Anticoagulant Reversal and Other Antidotes | MyMerci
제안하기
0 / 2000

Anticoagulant Reversal and Other Antidotes

Unit 13 · Topic 64Anticoagulant Reversal and Other Antidotes
1.Mechanism of Action

Reversal agents work in one of four ways:

MechanismExample
Binds the drug directly and neutralizes itProtamine (positively charged, binds negatively charged heparin); idarucizumab (antibody fragment that binds dabigatran); digoxin immune Fab (binds digoxin)
Replaces what the drug removedVitamin K lets the liver make active factors II, VII, IX, and X again; prothrombin complex concentrate (PCC) supplies those factors immediately; plasma supplies all factors
Blocks the receptorNaloxone (opioid receptor), flumazenil (benzodiazepine site), atropine (muscarinic receptor)
Blocks toxic metabolism or restores an enzymeFomepizole (alcohol dehydrogenase), acetylcysteine (glutathione), pralidoxime (acetylcholinesterase), methylene blue (reduces methemoglobin)

Timing matters: vitamin K takes hours, so it is paired with PCC for serious bleeding; protamine only reverses heparin still in the blood (UFH half-life about 1–2 hours).

2.Indications & Key Drugs

Anticoagulant and bleeding reversal

AnticoagulantReversalKey point
Unfractionated heparin (IV)Protamine sulfate — about 1 mg per 100 units of heparin given in the previous 2–3 hours; maximum 50 mg per dose; slow IVMonitor aPTT or anti-Xa after
LMWH (enoxaparin)Protamine (1 mg per 1 mg enoxaparin within 8 hours) — partial reversal onlyAnti-Xa activity only about 60% neutralized
Warfarin — major or life-threatening bleeding4-factor PCC + vitamin K 5–10 mg by slow IV infusionPlasma if PCC unavailable (larger volume, slower)
Warfarin — INR high, no bleedingINR above range but below 4.5: hold or lower dose. INR 4.5–10: hold doses; routine vitamin K not recommended. INR above 10: hold and give oral vitamin K (e.g., 2.5–5 mg)Recheck INR in 24 hours
DabigatranIdarucizumab 5 g IV (two 2.5 g vials)Dabigatran is also removed by hemodialysis
Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban)4-factor PCC in the USAndexanet alfa was withdrawn from the US market in December 2025; availability elsewhere may differ
Thrombolytics (alteplase, tenecteplase)Stop infusion; cryoprecipitate (fibrinogen); tranexamic acid or aminocaproic acidNeuro checks — intracranial hemorrhage

For every anticoagulant: also give local pressure, blood products as needed, and activated charcoal for a recent oral overdose if the airway is safe.

Other antidotes

PoisonAntidoteKey points
DigoxinDigoxin immune FabVials ≈ (serum digoxin in ng/mL × weight in kg) ÷ 100, or empiric vials for acute ingestion; potassium falls after Fab
AcetaminophenAcetylcysteineSee Topic 62
OpioidsNaloxoneTitrate to breathing
BenzodiazepinesFlumazenilSeizure risk
OrganophosphatesAtropine, pralidoximeTitrate to dry secretions
Beta blockers / CCBsGlucagon, calcium, high-dose insulinSee Topic 63
Methanol, ethylene glycolFomepizolePlus dialysis
CyanideHydroxocobalaminRed skin and urine
IronDeferoxamine IVFor severe poisoning (shock, acidosis, altered mental status, or serum iron above about 500 mcg/dL [90 µmol/L]); "vin rosé" (reddish) urine
Methemoglobinemia (dapsone, nitrates, benzocaine and other topical anesthetics)Methylene blue 1–2 mg/kg IV over 5 minutesChocolate-brown blood; SpO₂ reads about 85%
Anticholinergic deliriumPhysostigmine (selected, pure anticholinergic cases)Not in tricyclic overdose
SulfonylureasDextrose + octreotideOctreotide prevents rebound hypoglycemia
Isoniazid (seizures)PyridoxineSeizures resist usual drugs
Tricyclic antidepressantsSodium bicarbonateQRS > 100 ms
Local anesthetic systemic toxicity20% lipid emulsionBolus about 1.5 mL/kg, then infusion
Malignant hyperthermiaDantrolene 2.5 mg/kg IVSterile water diluent
Serotonin syndromeCyproheptadine (plus benzodiazepines, cooling)Oral or by NG tube only
Magnesium toxicityCalcium gluconate10 mL of 10% IV over about 3 minutes
MethotrexateLeucovorin (folinic acid); glucarpidaseLeucovorin rescue on schedule
Rocuronium, vecuroniumSugammadexBackup contraception for 7 days
LeadChelation (succimer, edetate calcium disodium)Remove the source; never confuse with edetate disodium (fatal hypocalcemia)
3.Adverse Effects
DrugKey adverse effects
ProtamineBoxed warning: hypotension, cardiovascular collapse, anaphylaxis, pulmonary hypertension, bradycardia — especially with fast injection; excess protamine itself prolongs clotting
Vitamin K (phytonadione) IVBoxed warning: severe hypersensitivity reactions, including fatal anaphylaxis, with IV or IM use — IV only when needed, diluted and infused slowly; SC absorption is unreliable and IM causes hematoma in coagulopathy
4-factor PCCBoxed warning: arterial and venous thrombosis (stroke, MI, PE); contains heparin in some products
PlasmaVolume overload (TACO), TRALI, allergic reactions; needs thawing and ABO matching
IdarucizumabThromboembolism once anticoagulation is removed; headache; hypokalemia
Digoxin immune FabHypokalemia, worsening HF, rapid ventricular rate in atrial fibrillation, allergic reaction
DeferoxamineHypotension with rapid infusion; ARDS with prolonged infusion (beyond about 24 hours)
Methylene blueBlue-green urine and skin; boxed warning: serotonin syndrome with serotonergic drugs; hemolysis in G6PD deficiency
PhysostigmineBradycardia, asystole, seizures, bronchorrhea
4.Contraindications, Cautions & Interactions
  • Protamine: higher allergy risk in clients with fish allergy, prior protamine exposure (including NPH or protamine-zinc insulin), and vasectomy; give slowly (no faster than about 5 mg/min).
  • 4-factor PCC is contraindicated in DIC and in heparin-induced thrombocytopenia (it contains heparin), and with known anaphylaxis to its components; use caution after thromboembolism, MI, or stroke within the past 3 months.
  • Vitamin K: high doses make re-anticoagulation with warfarin difficult for days — use the smallest dose that fits the goal in clients who must stay anticoagulated (e.g., mechanical valve).
  • Idarucizumab: contains sorbitol — caution in hereditary fructose intolerance.
  • Methylene blue: contraindicated in G6PD deficiency (ineffective and causes hemolysis) and generally avoided with SSRIs, SNRIs, and MAOIs (serotonin syndrome).
  • Physostigmine: avoid with tricyclic antidepressant overdose, wide QRS, bradycardia, asthma, or bowel obstruction.
  • Pregnancy: warfarin is teratogenic; reversal and antidotes are given for maternal emergencies. Methylene blue is avoided in pregnancy when possible (fetal harm with intra-amniotic use), but may be used when maternal life is at risk.
  • Restarting anticoagulation: after bleeding is controlled, clients with strong thrombosis risk need a plan — reversal leaves them exposed to clots.
5.Monitoring & Nursing Interventions

Listed in priority order.

  1. Recognize bleeding — hypotension, tachycardia, falling hemoglobin, headache or neuro change (intracranial hemorrhage), black or bloody stools, hematuria, bleeding from lines. Stop the anticoagulant infusion and notify.
  2. Airway and circulation — two large-bore IVs, type and crossmatch, blood products as ordered; neuro checks for suspected intracranial bleeding.
  3. Know which anticoagulant, what dose, and when — the reversal choice and protamine dose depend on the drug, amount, and time of the last dose; check kidney function (DOAC clearance).
  4. Give reversal agents safely
    • Protamine: slow IV push or infusion over about 10 minutes, BP and HR during and after; resuscitation equipment ready
    • Vitamin K IV: diluted, slow infusion, observe for flushing, chest tightness, hypotension
    • PCC: reconstitute per label, infuse at the labeled rate; watch for thrombosis (chest pain, limb swelling, stroke signs)
    • Idarucizumab: two consecutive infusions or bolus injections
  5. Monitor response — aPTT or anti-Xa (heparin) 5–15 minutes after protamine and again later (heparin rebound); INR after PCC (about 30 minutes) and after vitamin K; hemoglobin and platelets; clinical bleeding
  6. Other antidotes — potassium and rhythm after Fab; BP during deferoxamine; methemoglobin level (co-oximetry) and urine color after methylene blue; ECG for sodium bicarbonate
  7. Document times of every dose and response; plan with the team when to restart anticoagulation
6.Client Education
  • Warfarin: keep INR appointments; consistent vitamin K intake (do not suddenly increase or stop green leafy vegetables); report new medicines, antibiotics, and herbal products
  • DOACs: take on time; do not double a missed dose; tell every provider and dentist; carry a wallet card
  • Report signs of bleeding: black stools, blood in urine, coughing or vomiting blood, severe headache, unusual bruising, prolonged nosebleeds
  • After a fall or head injury while on an anticoagulant, seek care even if you feel fine
  • After reversal: explain that clot risk is temporarily higher and anticoagulation may be restarted
  • Iron tablets and adult vitamins with iron are dangerous to small children — store locked
  • Clients who received methylene blue: urine may be blue-green for a day or two; clients who received hydroxocobalamin: red skin and urine are expected
7.Toxicity, Overdose & Antidotes
ProblemFindingsManagement
Heparin overdoseBleeding, prolonged aPTTStop infusion; protamine
Warfarin excessHigh INR ± bleedingHold; oral vitamin K if INR above 10; 4F-PCC + IV vitamin K for major bleeding
Superwarfarin rodenticide (brodifacoum)Prolonged, severe coagulopathyVitamin K for weeks to months; PCC or plasma for bleeding
DOAC excessBleedingIdarucizumab (dabigatran); 4F-PCC (factor Xa inhibitors, US)
Protamine excess or reactionHypotension, bronchospasm, bleedingStop; epinephrine for anaphylaxis; supportive
Reversal-related thrombosisStroke, MI, DVT/PE after PCC or idarucizumabReport new symptoms at once
Digoxin toxicityDysrhythmias, hyperkalemiaDigoxin immune Fab; potassium monitoring
Iron overdoseVomiting, GI bleeding, then latent phase, then shock, acidosis, liver failureDeferoxamine; whole-bowel irrigation
8.High-Yield Points
  • Heparin → protamine (about 1 mg per 100 units, max 50 mg, slow IV); LMWH reversal is only partial
  • Warfarin → vitamin K; major bleeding → 4-factor PCC + IV vitamin K
  • INR above 10 without bleeding → hold and oral vitamin K
  • Dabigatran → idarucizumab
  • Factor Xa inhibitors → 4-factor PCC in the US (andexanet alfa withdrawn December 2025)
  • IV vitamin K and protamine → give slowly (anaphylaxis, hypotension)
  • PCC carries a thrombosis boxed warning
  • Digoxin → digoxin immune Fab; watch for hypokalemia afterward
  • Iron → deferoxamine (vin rosé urine); methemoglobinemia → methylene blue (not in G6PD deficiency)
  • Sulfonylurea → octreotide; isoniazid → pyridoxine; TCA → sodium bicarbonate; magnesium → calcium gluconate

Country Notes

United States

  • Andexanet alfa sales ended in the US on December 22, 2025; hospital protocols now use 4-factor PCC for factor Xa inhibitor–associated major bleeding.
  • Idarucizumab and 4-factor PCC are usually stocked in emergency departments and blood banks; the pharmacist or blood bank prepares them.

Philippines

  • Warfarin remains common because of cost, so INR monitoring and dietary teaching are especially important; PCC may be limited, and fresh frozen plasma plus IV vitamin K is often the available reversal for warfarin bleeding.
  • Availability of idarucizumab and other specific antidotes varies by hospital; check the local formulary and the nearest referral center.
  • G6PD deficiency is part of national newborn screening; ask about it before giving methylene blue or other oxidant drugs.

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습
컨텐츠를 그만볼래?

필기노트, 하이라이터, 메모는 잘 쓰고 있어?

내보내줘
어떤 폴더에 저장할래?

컨텐츠 노트에는 총 0개의 폴더가 있어!

폴더 만들기
컨텐츠 만들기
만들기
신고했어요.

운영진이 검토할게요!

해당 유저를 차단했어요.

마이페이지에서 차단한 회원을 관리할 수 있어요.